Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Stephen How who wrote (924)	5/8/1998 12:52:00 AM
From: Jim Roof	Respond to of 1432

Let's try to argue on the basis of science - not history. History can prove nothing and even cannot itself be proven by scientific methods. Crossen's past may be interesting but it will be science that determines if Hextend is viable and attractive. Jim

To: Stephen How who wrote (924)	5/8/1998 8:47:00 AM
From: Saul H Rosenthal	Read Replies (1) \| Respond to of 1432

Here's his profile: David Crossen is a Senior Managing Director and Senior Research Analyst in the Health Care Group at NationsBanc Montgomery Securities, where he follows biotechnology companies. Amgen, Inc., North American Vaccine, Inc., Biochem Pharma and The Liposome Company are among the companies in Crossen's current research coverage. Crossen joined NationsBanc Montgomery Securities in 1995. Prior to joining NationsBanc Montgomery, Crossen served as a Managing Director and Director of Health Care Research at UBS Securities. He was CEO of Cortech, Inc. for six years and a Pharmaceutical Analyst and Partner at Sanford C. Bernstein & Co. Sorry, but he doesn't sound like a dummy to me!